WORK AND RESEARCH INTERESTS

Basic Research in Knee Osteoarthritis (KOA)
My research focuses on developing cellular and immunomodulatory therapies for knee osteoarthritis (KOA). Specifically, we investigate mechanisms of action of mesenchymal stromal cells (MSC) in KOA, focusing on their interaction with monocytes/macrophages, and conduct clinical translational research. To learn more about our MSC research, click here.
In parallel, we have been exploring the role of different macrophage and monocyte subsets in experimental OA models and are looking at adoptive immunotransfer of re-programmed monocyte/macrophages as well as endogenous methods to in situ reprogram them. To learn more about our monocyte/macrophage research, click here.
As a third pillar, we have been developing novel, human tissue, diseased models of KOA. This included static, joint-on-dish models as well as more dynamic joint-on-chip models. To learn more about this line of research, click here.
MESENCHYMAL STROMAL CELLS
01
Enhanced MSCs
Our lab explores the transient culture priming strategies to augment the therapeutic potency of MSCs for osteoarthritis (OA). Specifically, we have engineered a proprietary 3D culture method and are comparing the 3D MSCs to MSCs cultured in 2D under hypoxic or normoxic conditions. We are also evaluating microRNA or transgene overexpression to genetically modify MSCs. We have been working with engineered IPSCs, differentiated to MSCs to explore genetically modified MSCs in KOA.
02
MSC Extracellular Vesicles (EVs)
We are also exploring EVs from MSCs, both enhanced and non-enhanced to understand if MSC effects are mediated by EVs and whether the enhancement that improve MSC immunomodulatory effects are mediated by EVs. Apoptotic vesicles produced by MSCs are also being studied in this context.
03
MSC and Mitochondria
Mitochondria is being extracted from MSCs and compared to other cellular sources for use as a novel therapeutic in KOA. Enhanced MSCs are also being considered as sources for mitochondrial isolation and purification. Dr. Viswanathan is Co-PI and part of the MITO-2, NFRF-T grant initiative with Professor Ana Andreazza.
04
MSC Mechanisms of Action
MSC secretome, EVs, apoptotic vesicles and their interactions with monocytes and macrophages are being studied. We are particularly interested in MSC-mediated metabolic and epigenetic reprogramming of long lived peripheral macrophages in the knee joints. We published invited reviews on MSCs in KOA Nature and Cell Stem Cell reviews.
05
MSC Critical Quality Attributes
The extracellular matrix of bone comprises primarily mineralized collagen fibrils, which have a uniquely intricate ultrastructural arrangement of apatite mineral and collagen. Researchers have developed in vitro approaches to recreating mineralized collagen ultrastructure in bone. However, our understanding of how MSCs, which are used to study osteogenic differentiation in vitro, respond to ultrastructurally biomimetic mineralized collagen fibrils is an area of emerging interest.
06
MSC and Heterogeneity
With collaborator, Professor Julie Audet, we are exploring statistical and mechanistic models to understand the interplay between MSC donor heterogeneity and culture parameters, and how they dually impact both MSC cell expansion and MSC immunomodulatory and angiogenic properties. This work is setting the basis for Bayesian Optimization and other machine learning approaches.
MONOCYTES AND MACROPHAGES
01
Ontogeny and Transcriptional Diversity
The lab has been exploring the role of different macrophage and monocyte subsets in experimental OA models, using transgenic mice from Prof. Slava Epelman to lineage trace the bone marrow origin of monocytes and macrophages. Additionally, we are also using tamoxifen inducible transgenic mice to temporally ablate specific macrophages, including long-lived, macrophage subsets to understand their roles during experimental OA. Single cell transcriptomics and epigenomics study will allow us to better dissect functional roles of embryonically derived macrophages.
02
Adoptive Transfer of Macrophages
Using gene targets from these omics studies, we can engineer embryonic stem cell or iPSC-derived macrophages as the basis for adoptive transfer immunotherapy. There are research collaborations with Prof. Michael Laflamme’s lab and an industry partner to explore this.
03
Endogenous Reprogramming
Endogenous re-programing of long-lived, embryonically derived, resident macrophages and adult, bone marrow-derived recruited macrophages are also being attempted using several different methods including nanoparticles, probiotics, short chain fatty acid, and mitochondrial transplant.
04
Mechanisms of Action
We are exploring mechanisms of macrophage reprogramming including understanding histone modifications and metabolic reprogramming and how this impacts functional states of macrophages.
OSTEOARTHRITIS MODELS
01
Static Models
We have developed in vitro joint-on-dish static explant tissue-based KOA which was published in Osteoarthritis and Cartilage and cited as Top 10 2021 research advances by Arthritis Society Canada. Using this know-how we have now developed a joint-specific psoriatic arthritis (PsA) model with Professor Vinod Chandran as a research tool to study patient-specific responses to current PsA treatments.
02
Dynamic Models
Working with Professor Edmond Young, we have developed a microfluidics based, cartilage-on-chip model that is patient derived and capable to mimicking mechanical overloading. This work is currently under patent filing. There is a also a synovium-on-a-chip model that re-capitulates interstitial synovium lining layer in the joint with blood vessel network formation, and inclusion of syonvial fibroblasts and in future synovial macrophages